IL278464B2 - Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition - Google Patents
Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical compositionInfo
- Publication number
- IL278464B2 IL278464B2 IL278464A IL27846420A IL278464B2 IL 278464 B2 IL278464 B2 IL 278464B2 IL 278464 A IL278464 A IL 278464A IL 27846420 A IL27846420 A IL 27846420A IL 278464 B2 IL278464 B2 IL 278464B2
- Authority
- IL
- Israel
- Prior art keywords
- formula
- compound represented
- maleate
- present application
- crystal form
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2018/085617 WO2019210511A1 (zh) | 2018-05-04 | 2018-05-04 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL278464A IL278464A (enExample) | 2021-03-01 |
| IL278464B1 IL278464B1 (en) | 2024-06-01 |
| IL278464B2 true IL278464B2 (en) | 2024-10-01 |
Family
ID=68387039
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278464A IL278464B2 (en) | 2018-05-04 | 2018-05-04 | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
| IL312512A IL312512B2 (en) | 2018-05-04 | 2018-05-04 | S1P1 receptor agonist, its salt, its crystalline form, and its pharmaceutical composition |
| IL323665A IL323665A (en) | 2018-05-04 | 2025-09-29 | S1P1 receptor agonist, its salt, crystalline form, and pharmaceutical composition |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312512A IL312512B2 (en) | 2018-05-04 | 2018-05-04 | S1P1 receptor agonist, its salt, its crystalline form, and its pharmaceutical composition |
| IL323665A IL323665A (en) | 2018-05-04 | 2025-09-29 | S1P1 receptor agonist, its salt, crystalline form, and pharmaceutical composition |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11512078B2 (enExample) |
| EP (2) | EP4353719B1 (enExample) |
| JP (3) | JP7275253B2 (enExample) |
| KR (2) | KR102672632B1 (enExample) |
| AU (1) | AU2018421487B2 (enExample) |
| CA (1) | CA3099196A1 (enExample) |
| ES (1) | ES2978392T3 (enExample) |
| IL (3) | IL278464B2 (enExample) |
| MX (1) | MX2020011665A (enExample) |
| NZ (1) | NZ770323A (enExample) |
| SG (1) | SG11202010969UA (enExample) |
| WO (1) | WO2019210511A1 (enExample) |
| ZA (1) | ZA202007347B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL278464B2 (en) * | 2018-05-04 | 2024-10-01 | Suzhou Connect Biopharmaceuticals Ltd | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
| CA3201000A1 (en) * | 2020-11-09 | 2022-05-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050245575A1 (en) * | 2002-06-17 | 2005-11-03 | Weirong Chen | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists |
| CN105315266A (zh) * | 2014-08-01 | 2016-02-10 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型 |
| EP3048103A1 (en) * | 2013-09-22 | 2016-07-27 | Suzhou Connect Biopharmaceuticals, Ltd. | Immune adjustment compound, use thereof and pharmaceutical composition comprising same |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035538A1 (en) | 2002-10-15 | 2004-04-29 | Merck & Co., Inc. | Process for making azetidine-3-carboxylic acid |
| CN105348276B (zh) | 2014-08-22 | 2020-05-26 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的合成方法 |
| CN112778290B (zh) * | 2017-01-11 | 2022-12-06 | 苏州康乃德生物医药有限公司 | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 |
| IL278464B2 (en) * | 2018-05-04 | 2024-10-01 | Suzhou Connect Biopharmaceuticals Ltd | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition |
-
2018
- 2018-05-04 IL IL278464A patent/IL278464B2/en unknown
- 2018-05-04 NZ NZ770323A patent/NZ770323A/en unknown
- 2018-05-04 EP EP24155906.1A patent/EP4353719B1/en active Active
- 2018-05-04 AU AU2018421487A patent/AU2018421487B2/en active Active
- 2018-05-04 KR KR1020207034174A patent/KR102672632B1/ko active Active
- 2018-05-04 EP EP18917186.1A patent/EP3792258B1/en active Active
- 2018-05-04 MX MX2020011665A patent/MX2020011665A/es unknown
- 2018-05-04 US US17/052,160 patent/US11512078B2/en active Active
- 2018-05-04 WO PCT/CN2018/085617 patent/WO2019210511A1/zh not_active Ceased
- 2018-05-04 IL IL312512A patent/IL312512B2/en unknown
- 2018-05-04 CA CA3099196A patent/CA3099196A1/en active Pending
- 2018-05-04 SG SG11202010969UA patent/SG11202010969UA/en unknown
- 2018-05-04 KR KR1020247018420A patent/KR20240094023A/ko active Pending
- 2018-05-04 ES ES18917186T patent/ES2978392T3/es active Active
- 2018-05-04 JP JP2021510499A patent/JP7275253B2/ja active Active
-
2020
- 2020-11-25 ZA ZA2020/07347A patent/ZA202007347B/en unknown
-
2022
- 2022-10-06 US US17/961,270 patent/US12202822B2/en active Active
-
2023
- 2023-02-17 JP JP2023023091A patent/JP7651198B2/ja active Active
-
2024
- 2024-12-11 US US18/977,539 patent/US20250320200A1/en active Pending
-
2025
- 2025-03-06 JP JP2025035420A patent/JP2025074350A/ja active Pending
- 2025-09-29 IL IL323665A patent/IL323665A/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050245575A1 (en) * | 2002-06-17 | 2005-11-03 | Weirong Chen | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists |
| EP3048103A1 (en) * | 2013-09-22 | 2016-07-27 | Suzhou Connect Biopharmaceuticals, Ltd. | Immune adjustment compound, use thereof and pharmaceutical composition comprising same |
| CN105315266A (zh) * | 2014-08-01 | 2016-02-10 | 苏州康乃德生物医药有限公司 | 1-{2-氟-4-[5-(4-异丁基苯基)-1,2,4-噁二唑-3-基]-苄基}-3-吖丁啶羧酸的晶型 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250320200A1 (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| US11286259B2 (en) | Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof | |
| CN107344927A (zh) | Tafamidis葡甲胺盐的晶型E及其制备方法和用途 | |
| CN112778290B (zh) | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 | |
| TWI662031B (zh) | １－｛２－氟－４－［５－（４－異丁基苯基）－１，２，４－噁二唑－３－基］－苄基｝－３－吖丁啶羧酸的晶型 | |
| RU2822288C2 (ru) | Соль присоединения агониста рецептора s1p1 и ее кристаллическая форма и фармацевтическая композиция на ее основе | |
| CN105461610A (zh) | 一种阿普斯特的晶型及其制备方法、药物组合物和用途 | |
| CN106928228B (zh) | 奥格列汀盐及其晶型、它们的制备方法和药物组合物 | |
| HK40106546B (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| HK40106546A (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| HK40042284B (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| HK40042284A (en) | Addition salt of s1p1 receptor agonist and crystal form thereof, and pharmaceutical composition | |
| US20250243242A1 (en) | Levodopa tyrosine polymorphs | |
| BR112020022429B1 (pt) | Forma cristalina do maleato de agonista de receptor s1p1, seu método de preparação, seu uso e composição farmacêutica que o compreende | |
| BR122022025339B1 (pt) | Sulfato de agonista de receptor s1p1, forma cristalina do mesmo, seu método de preparação, seu uso, composição farmacêutica que o compreende e método para tratar e/ou prevenir doença mediada pelo receptor s1p1 | |
| BR122022025293B1 (pt) | Sal de sódio de agonista de receptor s1p1, forma cristalina do mesmo, seu método de preparação, seu uso, composição farmacêutica que o compreende e método para tratar e/ou prevenir doença mediada pelo receptor s1p1 |